|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
|
AU598946B2
(en)
|
1987-06-24 |
1990-07-05 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Nucleoside derivatives
|
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
BR9106702A
(pt)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals Inc |
Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
AU3222793A
(en)
|
1991-11-26 |
1993-06-28 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
|
TW393513B
(en)
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
US5820873A
(en)
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
|
ES2646630T3
(es)
|
2008-11-07 |
2017-12-14 |
Massachusetts Institute Of Technology |
Lipidoides aminoalcohólicos y usos de los mismos
|
|
AP2012006053A0
(en)
|
2009-06-02 |
2012-02-29 |
Brian Charles Keller |
Pure peg-lipid conjugates.
|
|
US8889394B2
(en)
|
2009-09-07 |
2014-11-18 |
Empire Technology Development Llc |
Multiple domain proteins
|
|
US20140141070A1
(en)
*
|
2011-07-06 |
2014-05-22 |
Andrew Geall |
Liposomes having useful n:p ratio for delivery of rna molecules
|
|
EP3349802B1
(en)
*
|
2015-09-14 |
2021-08-04 |
The Board of Regents of the University of Texas System |
Lipocationic dendrimers and uses thereof
|
|
EP3538515B1
(en)
*
|
2016-11-08 |
2022-07-20 |
Ramot at Tel-Aviv University Ltd. |
Cationic lipids for nucleic acid delivery and preparation thereof
|
|
WO2019204226A1
(en)
*
|
2018-04-16 |
2019-10-24 |
University Of Massachusetts |
Compositions and methods for improved gene editing
|
|
US12357580B2
(en)
*
|
2018-06-19 |
2025-07-15 |
The Board Of Regents Of The University Of Texas System |
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
|
|
WO2020051220A1
(en)
*
|
2018-09-04 |
2020-03-12 |
The Board of the Regents of the University of Texas System |
Compositions and methods for organ specific delivery of nucleic acids
|
|
CN112996519B
(zh)
*
|
2018-09-04 |
2025-02-28 |
德克萨斯大学系统董事会 |
用于核酸的器官特异性递送的组合物和方法
|
|
CA3121191A1
(en)
*
|
2018-11-28 |
2020-06-04 |
Crispr Therapeutics Ag |
Optimized mrna encoding cas9 for use in lnps
|
|
WO2020186213A1
(en)
*
|
2019-03-14 |
2020-09-17 |
The Broad Institute, Inc. |
Novel nucleic acid modifiers
|
|
WO2020241679A1
(ja)
*
|
2019-05-30 |
2020-12-03 |
国立大学法人北海道大学 |
脂質ナノ粒子
|
|
WO2022204043A1
(en)
*
|
2021-03-22 |
2022-09-29 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for targeted delivery to cells
|
|
JP2024511463A
(ja)
*
|
2021-03-22 |
2024-03-13 |
リコード セラピューティクス，インク． |
細胞への標的送達のための組成物および方法
|
|
EP4313004A4
(en)
*
|
2021-03-23 |
2025-01-15 |
Recode Therapeutics, Inc. |
Compositions and methods for targeted systemic delivery to cells
|
|
US20250281580A1
(en)
*
|
2021-04-05 |
2025-09-11 |
The Board Of Regents Of The University Of Texas System |
Compositions, methods and uses for treating cystic fibrosis and related disorders
|
|
US20240261440A1
(en)
*
|
2021-04-05 |
2024-08-08 |
The Board Of Regents Of The University Of Texas System |
Compositions, methods and uses for treating cystic fibrosis and related disorders
|
|
WO2023215790A1
(en)
*
|
2022-05-03 |
2023-11-09 |
The Board Of Regents Of The University Of Texas System |
Co-delivery of inhibitory nucleic acids and genome editors for tumor therapy
|